[Intestinal microbial biocenosis in patients with systemic lupus erythematosus treated with prednisolone].
This study of intestinal microflora included 60 patients with systemic lupus erythematosus (LE) and 30 ones with cardiologic problems (controls). LE was diagnosed using criteria of American Rheumatologic Association (1982). Activity of the disease was estimated based on the ECLAM index. Nineteen patients with grade II LE were given with prednisolone (15 mg/day) and 15 ones did not receive this treatment. The qualitative and quantitative composition of intestinal microflora was evaluated by bacteriological methods. Results of the study were analysed with the use of STATISTICA 6.0 software system (StatSoft). Prednisolone was shown to alter the qualitative composition of microflora and the structure of symbiotic interactions between different organisms. Specifically, colonic flora contained more enterococci and organisms possessed of hemolytic activity whereas quantitative composition remained practically unchanged. Enterococci and colibacilli with modified enzymatic activity became predominant forms. It is concluded that prednisolone therapy affects colonic microbiocenosis in patients with LE favouring the development of enterococci, atypical colibacilli, and organisms with hemolytic activity.
Gul'neva
M Iu
MIu
Shilkina
N P
NP
D001419:Bacteria / Q000254:growth & development / Q000302:isolation & purification*; D001424:Bacterial Infections / Q000150:complications* / Q000382:microbiology; D003106:Colon / Q000187:drug effects / Q000382:microbiology*; D003108:Colonic Diseases / Q000209:etiology* / Q000382:microbiology; D015169:Colony Count, Microbial; D004305:Dose-Response Relationship, Drug; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects / Q000382:microbiology; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use*; D012720:Severity of Illness Index
D005938:Glucocorticoids; D011239:Prednisolone